Organization | EddingPharm Oncology Co., LTD.

EddingPharm Oncology Co., LTD. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Hong Kong Hong Kong (2001)

Status: No NME R&D (2001)

Organization Overview

First Clinical Trial

2016

NCT02833155

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

EddingPharm Oncology Co., LTD. | EOC Pharma

Active Ingredients

Drugs in Phase 3 Trials (4)

entinostat (2 trials)

exemestane (aromasin) (2 trials)

lapatinib (tykerb) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 2 Trials (5)

Key: EddingPharm Oncology Co., LTD. (3) Acquired (2)

capecitabine (xeloda) (2 trials)

cisplatin (platinol) (1 trial)

oxaliplatin (eloxatin) (1 trial)

pembrolizumab (keytruda) (1 trial)

telatinib (2 trials)

Drugs in Phase 1 Trials (4)

eftilagimod alpha (1 trial)

eoc317 (1 trial)

paclitaxel (taxol) (1 trial)

telatinib mesylate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Neoplasms (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 13